FLNA

May 7, 2026

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Filana Therapeutics has reported its Q1 2026 financial results, highlighting progress in its TSC-related epilepsy program. The company is addressing an FDA Clinical Hold and has published promising preclinical data on simufilam. Despite a net loss of $10.3 million, Filana maintains a solid cash position with no debt.

FLNA

Apr 15, 2026

Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data

Filana Therapeutics announced the publication of preclinical data in 'Epilepsia' demonstrating that simufilam effectively attenuates seizure progression in a mouse model of Tuberous Sclerosis Complex (TSC). The study confirms previous findings and highlights the potential of simufilam as a treatment for TSC-related epilepsy, which affects around 45,000 individuals in the U.S. The company is addressing FDA inquiries related to a clinical hold.

FLNA

Nov 22, 2022

Cassava Sciences Announces $ 50 Million Registered Direct Offering of Common Stock  AUSTIN, Texas, Nov. 18 , 20 2 2 – Cassava Sciences , Inc. (Nasdaq: SAVA ) (the “Company” or “Cassava

FLNA

Nov 3, 2022

Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign  AUSTIN, Texas – November 3 , 20 2 2 – Cassava Sciences , Inc. (Nasdaq: SAVA), a clinical-stage biot

FLNA

Oct 27, 2022

Cassava Sciences Announces Expansion of Leadership Team  · Chris Cook , A Skilled Litigator, To Join Management Team as General Counsel · New Position Is Expected to Be Critical to Operations and Strate

FLNA

Aug 3, 2021

xFEFF; Encouraging Interim Results at 9 Months from an Open-Label Study of Simufilam in Patients with Alzheimer's Disease Lindsay H. Burns Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez Rojas, Evelyn Lopez-Bri

FLNA

Jun 21, 2021

xFEFF;   Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease  - Selection of Premier Research as CRO Marks Significant Milestone Toward Init

FLNA

Jun 11, 2021

xFEFF; Cassava Sciences Announces the Appointment of  Richard J. Barry to its Board of Directors  - Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and

FLNA

Mar 11, 2021

xFEFF;  Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam  AUSTIN, TX – March 9 , 2021 – Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company

FLNA

Feb 10, 2021

xFEFF; Cassava Sciences Announces $ 200 Million Registered Direct Offering of Common Stock  AUSTIN, Texas, Feb . 10 , 20 21 – Cassava Sciences, Inc. (Nasdaq: SAVA ) (the “Company” or “

FLNA

Feb 8, 2021

xFEFF; CASSAVA sciences We Focus on Alzheimer's disease February 2021 CASSAVA sciences 1  Forward-Looking Statements & Safe Harbor This presentation contains forward-looking statements, including statements made

FLNA

Jan 4, 2021

xFEFF; Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer  Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company'

FLNA

Nov 13, 2020

xFEFF; Cassava Sciences Announces Proposed Public Offering of Common Stock  AUSTIN, Texas, November 12 , 2020 – Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Science

FLNA

Nov 7, 2020

xFEFF; Sumifilam Significantly Improves Eleven CSF Biomarkers in a Randomized, Placebo-controlled, One-month Clinical Trial in Alzheimer's Disease Patients Lindsay BURNS, Hoau-Yan WANG, Zhe PEI, Kuo-Chieh LEE, Yaneicy GO

FLNA

Sep 14, 2020

xFEFF; CASSAVA sciences Final Results of a Phase 2b Study of Sumifilam in Alzheimer's Disease

FLNA

Dec 5, 2019

xFEFF; CASSAVA SCIENCES One-month Oral Treatment with PTI-125, a New Drug Candidate, Reduces CSF & Plasma Biomarkers of Alzheimer's Disease Late Breaking Oral Communication 12th Clinical Trials on Alzheimer's Disease (CT

FLNA

Mar 28, 2019

Pain Therapeutics, Inc.     Pain Therapeutics Announces Name Change to Cassava Sciences , Inc.   - Focus is on Neurodegenerative Diseases -  AUSTIN, TX – Mar

FLNA

Jan 31, 2019

xFEFF;  Pain Therapeutics, Inc.   Pain Therapeutics Announces Feedback from Recent Meeting with FDA on REMOXY  - Going Forward, We Will Be Silent Regarding Future Expectations for REMOXY -

FLNA

Oct 11, 2018

xFEFF; Pain Therapeutics, Inc.  For More Information Contact: Ruth Araya Pain Therapeutics, Inc. IR@pain trials.com (512) 501-2485  Pain Therapeutics Announces Appointment of Chief Financial Officer &#xFE

FLNA

Oct 4, 2018

xFEFF;  Pain Therapeutics, Inc. Overview of Neuroprotection Program Non-confidential October 2018 NASDAQ: PTIE COPYRIGHT © Pain Therapeutics, Inc. 2018 1   Forward-Looking Statements This pre

FLNA

Aug 20, 2018

xFEFF; Pain Therapeutics, Inc.   For More Information Contact: Ruth Araya Pain Therapeutics, Inc. IR@paintrials.com (512) 501-2485   Pain Therapeutics Announces Closing of $11.3 Million Re

FLNA

May 10, 2017

xFEFF; Pain Therapeutics, Inc.  For More Information Contact: Ruth Araya Pain Therapeutics, Inc. IR@pain trials.com (512) 501-2485   Pain Therapeutics Announces Reverse Stock Split - Stock to Trad

FLNA

May 10, 2013

JFIF
dd��Ducky
2��Adobed�
���         #"""#''''''''''
    !! !!''''''''''����
"

���







FLNA

May 2, 2007

v073384_ex991.txt Pain Therapeutics Announces First Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., May 2 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today r

FLNA

Feb 5, 2007

PAIN THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR-END 2006 FINANCIAL RESULTS SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a biopharmaceutical company, today repo

FLNA

Oct 25, 2006

PAIN THERAPEUTICS ANNOUNCES THIRD QUARTER 2006